Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature

• Publication date

  2013-10-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature12746PMID 24172896PMCID PMC4133787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

  2013cited by this paper
• HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

  2013cited by this paper
• Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

  2013cited by this paper
• Emergence of gp120 V3 Variants Confers Neutralization Resistance in an R5 Simian-Human Immunodeficiency Virus-Infected Macaque Elite Neutralizer That Targets the N332 Glycan of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein

  2013cited by this paper
• Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

  2012cited by this paper
• HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

  2012cited by this paper
• Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

  2012cited by this paper
• A Blueprint for HIV Vaccine Discovery.

  2012cited by this paper
• Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 in Rhesus Macaques: Implications for Use in Vaccine Studies

  2012cited by this paper
• Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

  2012cited by this paper
• Most rhesus macaques infected with the CCR5-tropic SHIVAD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains

  2012cited by this paper
• Broad neutralization coverage of HIV by multiple highly potent antibodies

  2011cited by this paper
• Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

  2011cited by this paper
• Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

  2011cited by this paper
• Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine

  2011cited by this paper
• Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

  2010cited by this paper
• Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

  2010cited by this paper
• Generation of the Pathogenic R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 by Serial Passaging in Rhesus Macaques

  2010cited by this paper
• Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

  2009cited by this paper
• Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1

  2009cited by this paper
• Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

  2007cited by this paper
• Medicinal chemistry: Best of both worlds?

  2005cited by this paper
• Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays

  2004cited by this paper
• Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies

  2002cited by this paper
• Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

  2001cited by this paper
• Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy.

  2001cited by this paper
• Short- and Long-Term Clinical Outcomes in Rhesus Monkeys Inoculated with a Highly Pathogenic Chimeric Simian/Human Immunodeficiency Virus

  2000cited by this paper
• Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma

  1999cited by this paper
• Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper

• HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice.

  2026cites this paper
• Reduction of the HIV-1 reservoir in T cells from people with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells

  2026cites this paper
• Searching for a HIV-1 Cure

  2026cites this paper
• B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism

  2026cites this paper
• A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer

  2025cites this paper
• Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review

  2025cites this paper
• Prolonged non-suppressible viremia sustained by a clonally expanded, genomically defective provirus with an immune-evasive HIV protein expression profile

  2025cites this paper
• Current methods for detecting and assessing HIV-1 antibody resistance

  2025cites this paper
• Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies

  2025cites this paper
• HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing

  2025cites this paper
• A Novel Antibody Against the Non-RBD Region of Middle East Respiratory Syndrome Coronavirus Spike Protein.

  2025cites this paper
• HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges

  2025cites this paper
• Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope

  2025cites this paper
• SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants

  2025cites this paper
• Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data

  2025cites this paper
• Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection

  2024cites this paper
• Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

  2024cites this paper
• Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates

  2024cites this paper
• Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions.

  2024cites this paper
• Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies

  2024cites this paper
• HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV vectored immunotherapy in humanized mice

  2024cites this paper
• Harnessing immune cells to eliminate HIV reservoirs

  2024cites this paper
• Preclinical animal models to evaluate therapeutic antiviral antibodies.

  2024cites this paper
• The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

  2024cites this paper
• RAIN: a Machine Learning-based identification for HIV-1 bNAbs

  2024cites this paper
• Interventions during Early Infection: Opening a Window for an HIV Cure?

  2024cites this paper
• Production and Characterization of Novel Anti-HIV Fc-Fusion Proteins in Plant-Based Systems: Nicotiana benthamiana & tobacco BY-2 cell suspension.

  2024cites this paper
• A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

  2024cites this paper
• Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques

  2024cites this paper
• RAIN: machine learning-based identification for HIV-1 bNAbs

  2024cites this paper
• Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV

  2023cites this paper
• Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure

  2023cites this paper
• Determination of Binding Affinity of Antibodies to HIV-1 Recombinant Envelope Glycoproteins, Pseudoviruses, Infectious Molecular Clones, and Cell-Expressed Trimeric gp160 Using Microscale Thermophoresis

  2023cites this paper
• Humanized Mice for Studies of HIV-1 Persistence and Elimination

  2023cites this paper
• Mapping the interplay between NK cells and HIV: therapeutic implications

  2023cites this paper
• Development of screening assays for use of broadly neutralizing antibodies in people with HIV

  2023cites this paper
• A contemporary and inflammatory triangle at the mucosa: HIV, antibodies and bacterial STIs.

  2023cites this paper
• Broadly neutralizing antibodies targeting HIV: Progress and challenges.

  2023cites this paper
• Magnetic Dendritic Polymer Nanospheres for High-Performance Separation of Histidine-Rich Proteins.

  2023cites this paper
• Antiviral neutralizing antibodies: from in vitro to in vivo activity

  2023cites this paper
• mAb therapy controls CNS‐resident lyssavirus infection via a CD4 T cell‐dependent mechanism

  2023cites this paper
• Engineering strategies of Anti-HIV antibody therapeutics in clinical development

  2023cites this paper
• Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

  2023cites this paper
• Next-generation bNAbs for HIV-1 cure strategies.

  2023cites this paper
• Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques

  2023cites this paper
• Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

  2022cites this paper
• Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article.

  2022cites this paper
• Implications of the 375W mutation for HIV-1 tropism and vaccine development

  2022cites this paper
• Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env

  2022cites this paper
• Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2

  2022cites this paper
• HIV-1 Vpu restricts Fc-mediated effector functions in vivo

  2022cites this paper
• Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques

  2022cites this paper
• Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection

  2022cites this paper
• Implications of the 375W mutation for HIV-1 tropism and vaccine development

  2022cites this paper
• HIV cure strategies: which ones are appropriate for Africa?

  2022cites this paper
• Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody

  2022cites this paper
• A new hypothesis on HIV cure [version 1; peer review: 2 approved]

  2022cites this paper
• Maternal immune protection against infectious diseases.

  2022cites this paper
• Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses

  2022cites this paper
• Progress Towards a Therapeutic HIV DNA Vaccine

  2022cites this paper
• An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect

  2022cites this paper
• The HIV Env Glycoprotein Conformational States on Cells and Viruses

  2022cites this paper
• Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo

  2022cites this paper
• Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.

  2021cites this paper
• TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption

  2021cites this paper
• Broadly neutralizing HIV-1 antibody reactivity in HIV tests: implications for diagnostics

  2021cites this paper
• Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

  2021cites this paper
• Vectored antibody gene delivery restores host B and T cell control of persistent viral infection.

  2021cites this paper
• Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission

  2021cites this paper
• Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.

  2021cites this paper
• Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression.

  2021cites this paper
• Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward

  2021cites this paper
• CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection

  2021cites this paper
• Broadly neutralizing antibodies for the treatment of HIV infection

  2021cites this paper
• Blocking α4β7 integrin delays viral rebound in SHIVSF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies

  2021cites this paper
• Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies

  2021cites this paper
• Broadly neutralizing antibodies for HIV-1 prevention and therapy.

  2021cites this paper
• Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir

  2021cites this paper
• A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody

  2021cites this paper
• Sequence and functional characterization of a public HIV-specific antibody clonotype

  2021cites this paper
• Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry

  2021cites this paper
• New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure

  2021cites this paper
• New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure

  2021cites this paper
• Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding

  2021cites this paper
• Neutralization Characteristics HIV-1 CRF01_AE Env Clones from Infections in China

  2021cites this paper
• Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application

  2021cites this paper
• Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor

  2020cites this paper
• Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics

  2020cites this paper
• Pathways towards human immunodeficiency virus elimination

  2020cites this paper
• Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies

  2020cites this paper
• Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

  2020cites this paper
• Nonhuman Primate Models for Antimicrobial Drug Discovery

  2020cites this paper
• Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs

  2020cites this paper
• Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

  2020cites this paper
• In Situ Cascade Derivation toward a Hierarchical Layered Double Hydroxide Magnetic Absorbent for High-Performance Protein Separation

  2020cites this paper
• COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research

  2020cites this paper
• Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1

  2020cites this paper
• Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence

  2020cites this paper
• Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

  2020cites this paper
• Escape of HIV-1 Envelope Glycoprotein from Restriction of Infection by IFITM3

  2020cites this paper